nach oben

04.04.2024 | Diabetische Retinopathie | Journal Club

Können SGLT-2-Inhibitoren das Risiko einer diabetischen Retinopathie vermindern?

verfasst von: Michael Jecht

Einloggen, um Zugang zu erhalten

Auszug

Yen F‑S, Wei JC‑C, Yu T‑S et al (2023) Sodium-glucose cotransporter 2 inhibitors and risk of retinopathy in patients with type 2 diabetes. JAMA Network Open 6(12):e2348431. …

Inzucchi SE, Wanner C, Hehnke U et al (2019) Retinopathy outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial. Diabetes Care 42(4):e53–e55CrossRefPubMed

Li C, Zhou Z, Neuen BL et al (2021) Sodium-glucose co-transporter‑2 inhibition and ocular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 23(1):252–257CrossRefPubMed

Ma Y, Lin C, Cai X et al (2022) The association between the use of sodium glucose cotransporter 2 inhibitor and the risk of diabetic retinopathy and other eye disorders: a systematic review and meta-analysis. Expert Rev Clin Pharmacol 15(7):877–886CrossRefPubMed

Zhou B, Shi Y, Fu R et al (2022) Relationship between SGLT-2i and ocular diseases in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Front Endocrinol 13:907340CrossRef

DeFronzo RA, Reeves WB, Awad AS (2021) Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol 17(5):319–334CrossRefPubMed

Wong CW, Wong TY, Cheng CY, Sabanayagam C (2014) Kidney and eye diseases: common risk factors, etiological mechanisms, and pathways. Kidney Int 85(6):1290–1302CrossRefPubMed

Lahoti S, Nashawi M, Sheikh O, Massop D, Mir M, Chilton R (2020) Sodium-glucose co-transporter 2 inhibitors and diabetic retinopathy: insights into preservation of sight and looking beyond. Cardiovasc Endocrinol Metab 10(1):3–13CrossRefPubMedPubMedCentral

Hu Y, Xu Li QH et al (2022) Dapagliflozin reduces apoptosis of diabetic retina and human retinal microvascular endothelial cells through ERK1/2/CPLA2/AA/ROS pathway independent of hypoglycemic. Front Pharmacol 13:827896CrossRefPubMedPubMedCentral

Wakisaka M, Nagao T (2017) Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy. Glycobiology 27(8):691–695CrossRefPubMedPubMedCentral

10.

Wakisaka M, Yoshinari M, Asano T et al (1999) Normalization of glucose entry under the high glucose condition by phlorizin attenuates the high glucose-induced morphological and functional changes of cultured bovine retinal pericytes. Biochim Biophys Acta 1453(1):83–91CrossRefPubMed

11.

Hanaguri J, Yokota H, Kushiyama A et al (2022) The effect of sodium-dependent glucose cotransporter 2 inhibitor tofogliflozin on neurovascular coupling in the retina in type 2 diabetic mice. Int J Mol Sci 23(3):1362CrossRefPubMedPubMedCentral

12.

Matthews J, Herat L, Rooney J, Rakoczy E, Schlaich M, Matthews VB (2022) Determining the role of SGLT2 inhibition with empagliflozin in the development of diabetic retinopathy. Biosci Rep 42(3):BSR20212209CrossRefPubMedPubMedCentral

Titel: Können SGLT-2-Inhibitoren das Risiko einer diabetischen Retinopathie vermindern?
verfasst von: Michael Jecht
Publikationsdatum: 04.04.2024
Verlag: Springer Medizin
Schlagwörter: Diabetische Retinopathie
Diabetische Retinopathie
Pioglitazon
Sulfonylharnstoffe
Typ-2-Diabetes
Diabetische Nephropathie
Empagliflozin
Natrium-Glukose-Kotransporter-2-Hemmer
Erschienen in: Die Diabetologie
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI: https://doi.org/10.1007/s11428-024-01178-w

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft.

Zu den Praxisempfehlungen

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Praxisempfehlungen der Deutschen Diabetes Gesellschaft